Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension.
N-terminal pro-brain natriuretic peptide
hemodialysis
home blood pressure
sacubitril/valsartan
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
05
01
2023
received:
06
11
2022
accepted:
07
01
2023
pubmed:
2
2
2023
medline:
11
3
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment, home blood pressure (BP), BP values during hemodialysis, and N-terminal pro-brain natriuretic peptide (NT-proBNP) level were measured. The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day. After 3 months, significant reductions in mean morning home BP (155 ± 17/80 ± 12 to 147 ± 16/76 ± 11 mmHg), mean nighttime home systolic BP (153 ± 19 to 144 ± 16 mmHg), and median (IQRs) NT-proBNP level [8124 (2620-13 394) to 6271 (1570-9591) pg/mL] were observed (all P < .05), whereas BP values during hemodialysis did not change significantly. In hemodialysis patients, except for hypotension, sacubitril/valsartan was generally well tolerated, effectively controlled out-of-office BP, and improved NT-proBNP.
Identifiants
pubmed: 36722379
doi: 10.1111/jch.14635
pmc: PMC9994168
doi:
Substances chimiques
azilsartan
F9NUX55P23
sacubitril
17ERJ0MKGI
Tetrazoles
0
Valsartan
80M03YXJ7I
Aminobutyrates
0
Biphenyl Compounds
0
Angiotensin Receptor Antagonists
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
304-308Informations de copyright
© 2023 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Références
J Clin Hypertens (Greenwich). 2022 Mar;24(3):300-308
pubmed: 35099841
J Clin Hypertens (Greenwich). 2023 Mar;25(3):304-308
pubmed: 36722379
Circulation. 2018 Oct 9;138(15):1505-1514
pubmed: 30002098
Hypertens Res. 2012 Aug;35(8):777-95
pubmed: 22863910
Hemodial Int. 2007 Jan;11(1):51-61
pubmed: 17257357
ESC Heart Fail. 2020 Dec;7(6):3841-3850
pubmed: 32977362
Kidney Int. 2020 May;97(5):861-876
pubmed: 32278617
Eur J Clin Pharmacol. 2016 Sep;72(9):1065-73
pubmed: 27230850
Hypertens Res. 2015 Apr;38(4):269-75
pubmed: 25693859
Hypertens Res. 2022 Jul;45(7):1097-1110
pubmed: 35501475
Front Med (Lausanne). 2022 Jul 19;9:877237
pubmed: 35928297
Clin Chem. 2004 Dec;50(12):2279-85
pubmed: 15364888
ESC Heart Fail. 2020 Jun;7(3):1125-1129
pubmed: 32153122
Diabetes Care. 2006 Jan;29 Suppl 1:S43-8
pubmed: 16373932
Nat Rev Nephrol. 2016 Oct;12(10):636-47
pubmed: 27573731
Semin Dial. 2015 Jul-Aug;28(4):330-6
pubmed: 25877881
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):9-18
pubmed: 28944989